利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.061 秒)

    ANTIBODIES TO IL-6 AND USE THEREOF
    12.
    发明申请
    ANTIBODIES TO IL-6 AND USE THEREOF 有权
    抗IL-6的抗体及其用途

    公开(公告)号：US20090297513A1

    公开(公告)日：2009-12-03

    申请号：US12391717

    申请日：2009-02-24

    申请人： Leon Garcia-Martinez ,  Anne Elisabeth Carvalho Jensen ,  Katie Olson ,  Ben Dutzar ,  Ethan Ojala ,  Brian Kovacevich ,  John Latham ,  Jeffrey T.L. Smith

    发明人： Leon Garcia-Martinez ,  Anne Elisabeth Carvalho Jensen ,  Katie Olson ,  Ben Dutzar ,  Ethan Ojala ,  Brian Kovacevich ,  John Latham ,  Jeffrey T.L. Smith

    IPC分类号： A61K39/395 ,  C07K16/24 ,  C07H21/04 ,  C12N15/63

    CPC分类号： C07K16/248 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76

    摘要： The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

    摘要翻译： 本发明涉及对IL-6具有结合特异性的抗体及其片段和人源化形式。 本发明的另一个实施方案涉及本文所述的抗体及其结合片段，其包含本文所述的VH，VL和CDR多肽的序列，以及编码它们的多核苷酸。 本发明还涉及抗IL-6抗体及其与一个或多个功能或可检测部分缀合的结合片段的缀合物。 本发明还考虑制备所述抗IL-6抗体及其结合片段的方法。 本发明的实施方案还涉及抗IL-6抗体及其结合片段用于诊断，评估和治疗与IL-6相关的疾病和病症的用途。 这些抗体可以结合可溶性IL-6，细胞表面表达的IL-6，IL-6 / IL-6R中的至少一种和/或阻止IL-6和IL-6R的结合，IL-6 / IL -6R和gp130，或者形成IL-6 / IL-6R / gp130多聚体，从而抑制与前述任何相关的生物学作用。

    ANTIBODIES TO IL-6 AND USE THEREOF
    14.
    发明申请
    ANTIBODIES TO IL-6 AND USE THEREOF 有权
    抗IL-6的抗体及其用途

    公开(公告)号：US20110293622A1

    公开(公告)日：2011-12-01

    申请号：US13152603

    申请日：2011-06-03

    申请人： Leon Garcia-Martinez ,  Anne Elisabeth Carvalho Jensen ,  Katie Olson ,  Ben Dutzar ,  Ethan Ojala ,  Brian Kovacevich ,  John Latham ,  Jeffrey T.L. Smith

    发明人： Leon Garcia-Martinez ,  Anne Elisabeth Carvalho Jensen ,  Katie Olson ,  Ben Dutzar ,  Ethan Ojala ,  Brian Kovacevich ,  John Latham ,  Jeffrey T.L. Smith

    IPC分类号： A61K39/395 ,  G01N33/566 ,  C40B30/04 ,  C07K16/24

    CPC分类号： C07K16/248 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/60 ,  C12N9/64 ,  C12N15/81 ,  C12P21/02

    摘要： The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

    摘要翻译： 本发明涉及对IL-6具有结合特异性的抗体及其片段和人源化形式。 本发明的另一个实施方案涉及本文所述的抗体及其结合片段，其包含本文所述的VH，VL和CDR多肽的序列，以及编码它们的多核苷酸。 本发明还涉及抗IL-6抗体及其与一个或多个功能或可检测部分缀合的结合片段的缀合物。 本发明还考虑制备所述抗IL-6抗体及其结合片段的方法。 本发明的实施方案还涉及抗IL-6抗体及其结合片段用于诊断，评估和治疗与IL-6相关的疾病和病症的用途。 这些抗体可以结合可溶性IL-6，细胞表面表达的IL-6，IL-6 / IL-6R中的至少一种和/或阻止IL-6和IL-6R的结合，IL-6 / IL -6R和gp130，或者形成IL-6 / IL-6R / gp130多聚体，从而抑制与前述任何相关的生物学作用。

    Antibodies to IL-6 and use thereof
    19.
    发明申请
    Antibodies to IL-6 and use thereof 审中-公开
    IL-6抗体及其用途

    公开(公告)号：US20100290993A1

    公开(公告)日：2010-11-18

    申请号：US12601295

    申请日：2008-05-21

    申请人： Leon Garcia-Martinez ,  Anne Elisabeth Carvalho ,  Katie Olson ,  Ben Dutzar ,  Ethan Ojala ,  John Latham ,  Brian Kovacevich ,  Jeffrey T.L. Smith

    发明人： Leon Garcia-Martinez ,  Anne Elisabeth Carvalho ,  Katie Olson ,  Ben Dutzar ,  Ethan Ojala ,  John Latham ,  Brian Kovacevich ,  Jeffrey T.L. Smith

    IPC分类号： A61K49/00 ,  A61K39/395 ,  G01N33/53 ,  C12N5/10 ,  C12N1/19 ,  C12N15/63 ,  G01N33/566 ,  C07K16/24 ,  C07H21/04 ,  A61P19/02 ,  A61P17/06 ,  A61P37/06 ,  A61P19/10 ,  A61P35/00 ,  A61P35/04 ,  A61P3/10 ,  A61P3/04 ,  A61P11/06 ,  A61P25/28 ,  A61P7/06 ,  A61P25/24 ,  A61P7/02 ,  A61P29/00

    摘要： The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

    摘要翻译： 本发明涉及对IL-6具有结合特异性的抗体及其片段。 本发明的另一个实施方案涉及本文所述的抗体及其结合片段，其包含本文所述的VH，VL和CDR多肽的序列，以及编码它们的多核苷酸。 本发明还涉及抗IL-6抗体及其与一个或多个功能或可检测部分缀合的结合片段的缀合物。 本发明还考虑制备所述抗IL-6抗体及其结合片段的方法。 本发明的实施方案还涉及抗IL-6抗体及其结合片段用于诊断，评估和治疗与IL-6相关的疾病和病症的用途。 这些抗体可以结合可溶性IL-6，细胞表面表达的IL-6，IL-6 / IL-6R中的至少一种和/或阻止IL-6和IL-6R的结合，IL-6 / IL -6R和gp130，或者形成IL-6 / IL-6R / gp130多聚体，从而抑制与前述任何相关的生物学作用。

    Antagonists of IL-6 to raise Albumin and/or lower CRP
    20.
    发明申请
    Antagonists of IL-6 to raise Albumin and/or lower CRP 有权
    IL-6拮抗剂可以提高白蛋白和/或降低CRP

    公开(公告)号：US20090291082A1

    公开(公告)日：2009-11-26

    申请号：US12323066

    申请日：2008-11-25

    申请人： Jeffrey T.L. Smith

    发明人： Jeffrey T.L. Smith

    IPC分类号： A61K39/395

    CPC分类号： C07K16/248 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2316/96 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/4737 ,  G01N2333/765 ,  G01N2800/52

    摘要： The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.

    摘要翻译： 本发明涉及使用IL-6拮抗剂如具有对IL-6具有结合特异性的抗体及其片段的改善生存能力或有需要的患者生活质量的治疗方法。 在优选实施方案中，这些患者将包括在治疗前显示（或有发展风险）升高的血清C-反应蛋白水平或降低的血清白蛋白水平的那些。 在另一个优选实施例中，患者的格拉斯哥预后评分将提高，并且生存能力将优选地得到改善。